Early treatment often best course in HIV An international panel has updated its guidelines on when to start treatment. With the risks of HIV antiretroviral therapy (ART) decreasing and concerns ...

SAN ANTONIO — HIV is no longer a death sentence for those who live with it, and new therapies with benefits lasting longer than what current medications can provide could help curb the epidemic even ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

In the quest to overcome quality-of-life altering side effects linked to combination antiretroviral therapy (cART) in people with HIV, a team of Johns Hopkins researchers has developed a new way to ...

Three individuals have been awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award for their work on the drug American Association for the Advancement of Science (AAAS) In the hunt for a ...

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir. ARTISTRY-1 is a phase 2, randomized, multicenter study that ...

Researchers conducted a retrospective, multinational study across 15 European treatment centers to assess the efficacy and tolerability of DTG/3TC vs BIC/TAF/FTC as first‑line therapy in ...

In the realm of health care, particularly in managing chronic conditions like Human Immunodeficiency Virus (HIV), knowledge and timely intervention are indispensable assets. Introducing your son to ...

– Positive Phase 3 Results from Both ARTISTRY-2 and ARTISTRY-1 Trials will Form the Basis of Regulatory Submissions – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today ...